RETATRUTIDE
KEY MECHANISM
THE "TRIPLE G" ACTION
ONE MOLECULE. THREE POWERFUL PATHWAYS. GREATER METABOLIC IMPACT.
A next-generation incretin agonist that simultaneously activates three key pathways—GIP, GLP-1, and glucagon—to help regulate appetite, improve metabolic function, and increase energy expenditure[cite: 9].
The "Triple G" Pathway Activation Overview[cite: 9]
THE THREE PATHWAYS
MULTI-TARGET RECEPTOR AGONISM
GIP
Glucose-Dependent Insulinotropic Polypeptide: Supports insulin secretion, nutrient utilization, and fat storage management[cite: 9].
GLP-1
Glucagon-Like Peptide-1: Helps reduce appetite, enhance satiety, and lower overall food intake[cite: 9].
GLUCAGON
Glucagon Receptor Activation: Helps increase energy expenditure, promote fat oxidation, and improve metabolic efficiency[cite: 9].
CLINICAL TRIAL RESULTS
SIGNIFICANT WEIGHT LOSS & METABOLIC BENEFITS
In the Phase 2 TRIUMPH-1 trial, retatrutide demonstrated dose-dependent reductions in body weight and improvements in key metabolic markers over 48 weeks (Mean baseline weight: -107 kg)[cite: 9].
Placebo
(n=71)[cite: 9]
1 mg
(n=68)[cite: 9]
4 mg
(n=72)[cite: 9]
8 mg
(n=72)[cite: 9]
Clinical Trial Weight Loss Benchmarks & Cardiometabolic Markers[cite: 9]
WEIGHT LOSS MILESTONES
PERCENTAGE ACHIEVED AT 8 MG (48 WEEKS)
Achieved $\ge 5\%$
Weight loss milestone[cite: 9]
Achieved $\ge 10\%$
Weight loss milestone[cite: 9]
Achieved $\ge 20\%$
Weight loss milestone[cite: 9]
CARDIOMETABOLIC MARKERS
IMPROVEMENTS AT 8 MG (48 WEEKS)
Triglycerides
Mean reduction[cite: 9]
LDL Cholesterol
Mean reduction[cite: 9]
HbA1c
Mean reduction[cite: 9]